Adalvo’s Lisdexamfetamine 10mg/ml Oral Solution has secured approvals in the EU, with US submission upcoming. To our knowledge, we are the first and only company to secure approval for Lisdexamfetamine Oral Solution in Europe.
This product represents a value-added version of Lisdexamfetamine, available as a ready-to-use oral solution, and targeting a child-friendly approach as a CNS drug indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).
Lisdexamfetamine INN had a total global sales of $6.1bn in 2023 with a 3Y CAGR of 10%, according to IQVIA.
Adalvo continues to uphold its commitment to delivering high-quality, value-added, differentiated solutions to its partners. There are no half-measures at Adalvo – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward.
Reach Out If Interested